Publications

Welcome to the publications page of the Framingham Heart Study Brain Aging Program (FHS-BAP), where we showcase the groundbreaking research driving advancements in Alzheimer’s Disease (AD) understanding. Our program is committed to revolutionizing AD research through a comprehensive approach that integrates surveillance, discovery, and collaboration. Here, you will find our latest publications, which reflect our work in enhancing cognitive decline assessments, brain imaging techniques, and the revitalization of our brain donation program. These publications highlight key findings in genetic factors, risk markers, and biomarkers related to AD, all aimed at fostering a global research community and accelerating the identification of therapeutic targets. Explore our research to learn more about our mission to uncover the biological foundations of AD and contribute to the preservation of cognitive health.

Comparison of Commonly Measured Plasma and Cerebrospinal Fluid Proteins and Their Significance for the Characterization of Cognitive Impairment Status

Abstract Background: Although cerebrospinal fluid (CSF) amyloid-β42 peptide (Aβ42) and phosphorylated tau (p-tau) and blood p-tau are valuable for differential diagnosis of Alzheimer's disease (AD) from cognitively normal (CN) there is a lack of validated biomarkers for mild cognitive impairment (MCI). Objective: This study sought to determine how plasma and CSF protein markers compared... More

Tagged: , ,